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Abstract Introduction: Potentially inappropriate medication (PIM) use in older adults with dementia is an
understudied area. We assessed longitudinal changes in PIM exposure by dementia type following
dementia diagnosis.
Methods: We followed 2448 participants aged65 years (52%women, 85.5%Caucasian, mean age
80.9 6 7.5 years) diagnosed with dementia after enrollment in the National Alzheimer’s Coordi-
nating Center (2005–2014). We estimated the association between dementia type and PIM annually
for 2 years after diagnosis, using Generalized Estimating Equations.
Results: Participants with Lewy body dementia had more PIM use, and participants with frontotem-
poral dementia had less PIM use than participants with Alzheimer’s disease. In the first year following
diagnosis, total number of medications increased, on average, by 10% for Alzheimer’s disease and
15% for Lewy body dementia (P , .05 for both).
Discussion: A tailored approach aimed at optimizing drug therapy is needed to mitigate PIM expo-
sure to improve medical care for individuals with dementia.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Dementia; Inappropriate medication use; National Alzheimer’s Disease Coordinating Center; Beers’ Criteria;
Polypharmacy
1. Introduction
Optimal drug therapy aimed at avoiding the prescription
of potentially inappropriate medications (PIMs),
prescribing beneficial medications, and minimizing total
number of medications is a challenge for clinicians treating
older adultswith dementia. For one, older adults with demen-
tia have more physical and mental health conditions and take
more medications to treat these conditions than older adults
without dementia [1–4]. In addition, older adults with
multiple diseases, including dementia, are often excluded
from drug trials, limiting the available evidence to guide
prescribing practices [5–8]. Furthermore, some studies
suggest that older adults with dementia experience
increased sensitivity to the side effects of medications
[8,9]. In addition, older adults with dementia experience
cognitive, affective, and behavioral changes that present
additional challenges to medication management [10–12].
A key component of optimal drug therapy is identifying
and deprescribing unnecessary and PIMs. Inappropriate
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prescribing in older adults is most commonly assessed by in-
dicators including the Beers’ Criteria [13], scales measuring
anticholinergic burden [14,15], and overall number of
medications [16–20]. Studies of PIM use in older adults
have found associations with increased risk of adverse
drug reactions [21], hospitalization and mortality [22], and
cognitive decline [23]. Studies of older adults with dementia
have found that exposure to polypharmacy (5 medications)
leads to worsening cognitive and functional abilities and
greater mortality [24,25]. Polypharmacy has also been
found to be associated with increased risk of dementia
[26,27] and PIM use among older adults with and without
dementia [16]. Recent attempts have been made to develop
a consensus list of inappropriate medication for people
with advanced dementia [28].
Despite these known risks, the prevalence of PIMuse among
individuals with dementia remains a clinical and public health
concern [16,20].A recent reviewof PIMuse among individuals
with cognitive impairment and dementia reported a prevalence
of 10.2%–56.4% across different samples in Europe, Australia,
and theUnited States [11]. Although there is a growing body of
evidence suggesting ahighprevalenceofPIMuse in individuals
with dementia [11], there is limited research evaluating changes
in PIM use in the years following dementia diagnosis [29]. In
addition, given the differences in etiology, clinical mani-
festation, and comorbidities associated with different types of
dementia, it would be expected that prescribing practices
should differ among individuals diagnosed with different types
of dementia [30–33]. In fact, previous studies suggested that
risk factors and medications’ effects may differ by the type of
dementia [34,35]. However, most studies to date are either
limited to a single type of dementia (i.e., Alzheimer’s disease
[AD]) or do not distinguish between different types of
dementia. Therefore, the aim of this study was to examine (1)
differences in PIM use by type of dementia diagnosis and (2)
longitudinal changes in PIM use in the 2 years following
diagnosis of common types of dementia.
2. Methods
2.1. Data source
The data for this studywere obtained from theNationalAlz-
heimer’s Disease Coordinating Center (NACC). A description
of the NACC cohort, its eligibility criteria, and data collection
are available elsewhere [36–39]. In summary, NACC was
established in 1999 with the purpose of facilitating research
related to AD. This cohort includes participants with AD and
related disorders, participants with mild cognitive
impairment, and cognitively normal participants. Participants
are enrolled through National Institute on Aging–funded
Alzheimer’s Disease Centers (ADC) based in university
medical centers and other institutes, mostly in urban areas
throughout the United States. Participants undergo a
comprehensive cognitive, behavioral, and functional
assessment at their initial study visit and at annual follow-up
visits until they are deceased or decline further participation
in the study. Beginning in 2005, Uniform Data Set (UDS)
data were collected through standardized evaluations of enro-
lees from National Institute on Aging–funded ADCs.
2.2. Sample
Our study included participants aged65 years, diagnosed
with dementia after enrollment in the NACC cohort. Partici-
pants were excluded if they: (1) enrolled after 2014
(n5 1180); (2) had a diagnosis of dementia at their initial visit
(prevalent dementia; n 5 12,046); (3) had only one NACC
assessment (n5 1065); (4) were not diagnosed with dementia
during the follow-up (n5 17,012); (5) were,65 years at the
visit in which incident dementia diagnosis occurred (n5 204);
(6) had a Clinical Dementia Rating (CDR) global score indi-
cating normal cognition at the visit of incident dementia diag-
nosis (n 5 7); or (7) had a primary dementia diagnosis of
“other” (n 5 143). As the aim of this study was to evaluate
PIM use among individuals with progressive dementias, we
sought to exclude thosewhose dementiamay have been related
to treatable/reversible conditions or for whom etiologywas un-
known [40,41]. The analytic sample for this study includes
2448 participants who enrolled in NACC between 2005 and
2014 and had an incident diagnosis of Alzheimer’s dementia
(AD: n 5 2090), vascular dementia (VD: n 5 136), Lewy
body dementia (LBD: n 5 144), or frontotemporal dementia
(FTD: n 5 78) after their initial visit (Fig. 1).
2.3. Measures
2.3.1. Dementia diagnosis
All participants in our study were deemed to have demen-
tia if they met the standard criteria for dementia of the Alz-
heimer’s type or for other non-Alzheimer’s-related
dementias based on comprehensive neuropsychiatric battery
and cognitive assessment with a trained ADC clinician
[37,42,43]. Our analyses only included incident dementia
cases, specifically those that were identified as such after
enrollment in the NACC cohort.
For our study, participants were grouped into mutually
exclusive groups based on the clinician’s determination of
their primary etiology of dementia at the visit of their inci-
dent dementia diagnosis.
1. Alzheimer’s disease [44] (n 5 2090). Participants
were considered to have AD if they met the criteria
for dementia and had probable AD as the primary clin-
ical diagnosis based on the National Institute of
Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Dis-
orders Association criteria.
2. Vascular dementia (n 5 136). Included participants
identified with stroke, probable VD, possible VD, or
any significant vascular brain injury as the primary
cause of dementia.
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3. Lewy body dementia (n5 144). Included participants
with LBD listed as the primary etiologic diagnosis on
the UDS clinician diagnosis form.
4. Frontotemporal dementia (n 5 78). Included partici-
pants with FTD as their primary cause of dementia
on the UDS clinician diagnosis form.
2.3.2. Potentially inappropriate medication use
Medication use was assessed based on the information
provided by the participant and/or the caregiver/legally
authorized representative (LAR) who accompanies them
for visits. Participants were asked to bring all medications
(or their medication list) they had taken in the past 2 weeks.
Medication use assessment included all prescription and
over-the-counter medications and was conducted using the
“brown bag” medication review approach [37]. Based on
these medication records, the following outcome variables
were created.
2.3.2.1. Beers’ Medication Criteria [13]
We used the 2015 updated Beers’ Criteria to identify
participants using PIM independent of diseases. We created
a count of the total number of 2015 Beers’ Criteria me-
dications a participant reported taking at each annual visit,
independent of participants’ specific dementia diagnosis.
2.3.2.2. Anticholinergic Drug Scale score [14,15]
The Anticholinergic Drug Scale score (ADS) ranks anti-
cholinergic effects of medicines with a score between 0 and
3. A score of 0 is given to medicines with no known anti-
cholinergic activity, score 1 for medicines that have potential
anticholinergic effects based on receptor binding studies,
score 2 for medicines with reported anticholinergic adverse
events, usually at excessive doses, and score 3 for medicines
with profound anticholinergic properties. Each individual’s
score is the sum of the individual medication rankings and
was calculated for each annual visit.
2.3.2.3. Total number of medications
A count of all medications a participant reported taking at
each annual visit, including over-the-counter medications,
supplements, and vitamins.
2.3.3. Other covariates
The following measures were recorded in the
NACC-UDS data set at each annual visit. Information was
obtained from the participant and/or the caregiver/LAR who
accompanies them for visits.
2.3.3.1. Sociodemographic characteristics
Sociodemographic characteristics include age, gender,
race/ethnicity (Caucasian, African American, or other), edu-
cation level (high school or less, college, or graduate), living
situation (lives alone, lives with a spouse or partner, or other
living situation), type of residence (single family residence,
retirement community, assisted living, or other), and level of
independence (able to live independently, requires assis-
tance, or completely dependent).
2.3.3.2. Health characteristics
We used the information recorded in the UDSHealth His-
tory form at the time of dementia diagnosis in the cohort. For
our analyses, we considered the following: cardiovascular
disease (myocardial infarction, atrial fibrillation, an-
gioplasty, coronary artery bypass graft surgery, pace maker,
congestive heart failure, or other cardiovascular disease),
stroke, diabetes (type 1 or type 2), and psychiatric diagnoses.
Body mass index was calculated from measures of the
participants’ height and weight. Smoking history (num-
ber of years the participant has smoked) was obtained
by self-report/LAR report.
2.3.3.3. CDR Global Score [45]
Dementia severity was assessed using this 5-point scale
to assess domains of cognitive and functional performance
and determine the level of impairment (none, questionable,
mild, moderate, or severe). The rating was obtained
Participants enrolled in NACC 2005-2014
N=32,266
Participants with no dementia at time of enrollment
N=21,079
Participants ≥ 65 at time of dementia diagnosis
N=2,598
Incident Dementia: 2,591
Alzheimer’s: 2,090 (80.7%)
Vascular: 136 (5.3%)
Lewy-body: 144 (5.5%)
Fronto-temporal: 78 (3.0%)
Other: 143 (5.5%)
Participants > 1 NACC assessment
N=20,014
Participants with incident dementia diagnosis
N=2,802
Cognitive Dementia Rating Scale > 0
N=2,591
Study Sample: 2,448
Alzheimer’s: 2,090 (85.4)
Vascular: 136 (5.6)
Lewy-body: 144 (5.9)
Fronto-temporal: 78 (3.2)
Fig. 1. Study flow chart for sample of 2380 NACC participants, 2005–2014.
Abbreviation: NACC, National Alzheimer’s Disease Coordinating Center.
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through a semi-structured interview by the ADC clinician
with the participant and his/her LAR. Our study excluded
individuals with no impairment as determined by the
CDR score.
2.3.3.4. Geriatric Depression Scale [46,47]
The 15-item Geriatric Depression Scale was used to
assess participants’ depressive symptoms at the visit.
2.4. Statistical analysis
For participants with different dementia diagnoses types,
we compared sociodemographic characteristics, comor-
bidities, and medication use at the visit they were diagnosed
with incident dementia during cohort participation (hereafter
referred to as baseline). For categorical variables, we used
chi-squared tests to identify overall differences across sub-
types of dementia. When a significant difference was identi-
fied at a level of P, .05, we conducted pairwise chi-squared
tests to identify differences between pairs of dementia
subtypes, applying a Bonferroni correction for multiple
comparisons. For continuous variables, we conducted an
analysis of variance, applying a Bonferroni correction for
multiple comparisons. All analyses were conducted using
SAS software, version 9.4 [48].
2.4.1. Modeling medication outcomes
To estimate each of the PIM use measures over the 2 years
following incident dementia diagnosis, we used generalized
estimating equations. This approach allows for the flexibility
to model correlation of within-subject repeated mea-
surements. Poisson distribution was applied to model count
outcomes. To account for the large number of participants
who were not taking any Beers’ Criteria medications
(24.8%) or had and ADS score 0 (41.0%), we modeled these
outcomes using only participants who had a Beers’ Criteria
medication count or ADS score  1 for at least one of the
time points in the respective models. A suitable working cor-
relation structure for each model was selected based on
quasi-information criterion fit-statistic. Models were
adjusted for sociodemographic and health characteristics
as described above (see Measures: other covariates). Finally,
differences in marginal means of PIM use by (1) type of de-
mentia diagnosis (compared to AD) and (2) time-by-type of
dementia interactions were estimated as least squares means
(LSMs).
2.4.2. Attrition and sensitivity analysis
We examined attrition from the study due to death, loss
to follow-up and declined participation, and due to
censoring (some participants who were diagnosed with de-
mentia in 2014 were only able to contribute 1 year of data
during this study period). To determine the impact of attri-
tion on the results of this study, we compared the estimates
obtained from the full sample to a subset of participants
(n 5 833) who participated in all three assessment points
in this study.
3. Results
3.1. Baseline characteristics
Overall, participants were 52% women, 85.5% Cauca-
sian, mean age was 80.9 6 7.8 years, and 74% completed
education beyond high school (Table 1). Participants with
FTD were younger, and participants with VD were older
than participants with other dementias. More participants
with LBD were male (74.3%) compared to other dementias
(all P, .05). Fewer participants with LBD (20.2%) and VD
(30.9%) were able to live independently than participants
with AD (35.0%, P , .01 for both). Participants with AD
and VD were more likely to live alone or have “other living
arrangements,” and participants with LBD and FTD were
more likely to be living with a spouse/partner (all P , .05).
More participants with VD had cardiovascular diseases
and history of stroke than participants with other dementias
(P , .01). Participants with LBD and FTD had fewer de-
pressive symptoms than participants with AD (P, .05). Par-
ticipants with AD had lower CDR scores (less impairment)
compared to VD and LBD (P , .05 for both).
In unadjusted analyses at baseline, there were no differ-
ences in the number of Beers’ Criteria medications by type
of dementia. ADS scores were higher among participants
with LBD compared to AD and FTD (P, .05 for both). Par-
ticipants with FTD reported taking fewer total medications
(mean: 5.9, SD: 3.3) compared to AD (mean: 7.2, SD:
4.1), VD (mean: 8.3, SD 5 4.3), or LBD (mean: 8.0, SD:
3.8) (all P , .05).
3.2. Longitudinal trends in PIM use by type of dementia
3.2.1. Differences in PIM use by type of dementia diagnosis
Participants with LBD had more PIM use than those with
AD, indicated by more Beers’ Criteria medications, higher
ADS scores, and higher total number of medications.
Compared to participants with AD, on average, over the
follow-up, participants with LBD were taking 21% more
Beers’ Criteria medications (LSM estimate: 1.21, 95% CI:
1.02–1.42; Fig. 2A displays by year), had ADS scores
32% higher (LSM: 1.32, 95% CI: 1.10–1.58; Fig. 2B
displays by year), and 12% more total medications (LSM:
1.12, 95% CI: 1.03–1.21; Fig. 2C displays by year).
Participants with FTD reported less PIM use than AD, indi-
cated by fewer Beers’ Criteria medications and lower count of
total medications (Figs. 2A–2C). Participants with FTD were
taking 24% fewer Beers’ Criteria medications (LSM: 0.76,
95% CI: 0.57–0.95) and 21% fewer total medications (LSM:
0.79, 95% CI: 0.69–0.90) over the follow-up than those with
AD. Participants with VD did not differ from participants
with AD on any measure of PIM use over the follow-up.
3.2.2. Changes in PIM use in the 2 years following
diagnosis
Number of Beers’ Criteria medications did not change
significantly over the follow-up for any type of dementia
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(Fig. 3A). Among participants with LBD, ADS scores
increased by 39% (LSM: 1.39, 95% CI: 1.17–1.66) in the first
year following dementia diagnosis and decreased in the sec-
ond year, such that there was no difference in ADS scores be-
tween and baseline and 2-year follow-up (LSM: 1.05, 95%
CI: 0.81–1.37) (Fig. 3B). ADS scores did not change signifi-
cantly over the follow-up for other dementias (Fig. 3B). In the
first year after diagnosis, total number of medications
Table 1
Baseline sociodemographic, health, and medication characteristics according to dementia diagnosis
Characteristics
Alzheimer’s disease
N 5 2090 (85.4%)
Vascular dementia
N 5 136 (5.6%)
Lewy body dementia
N 5 144 (5.8%)
Frontotemporal dementia
N 5 78 (3.2%)
All dementias
N 5 2448
Age in years mean (SD) 80.8 (7.7) 84.7 (7.6)1 78.0 (7.2)1,2 73.7 (6.4) 1–3 80.5 (7.8)
Female, N (%) 1118 (53.5) 75 (55.2) 37 (25.7)1,2 38 (48.7)3 1268 (51.8)
Race, N (%)
White 1776 (85.0) 109 (80.2) 133 (92.4)2 72 (92.3) 2090 (85.5)
Black 228 (10.9) 22 (16.2) 7 (4.9) 2 (2.6) 259 (10.6)
Other 86 (4.1) 5 (3.7) 4 (2.8) 4 (5.1) 99 (3.9)
Education, N (%)
High school or less 543 (26.0) 37 (27.2) 36 (25.0) 13 (16.7) 629 (25.7)
College 857 (41.0) 59 (43.4) 55 (38.2) 39 (50.0) 1010 (41.4)
Graduate 684 (32.7) 40 (29.4) 53 (36.8) 25 (32.1) 802 (32.6)
Living situation, N (%)
Lives alone 525 (25.1) 34 (25.0)1 14 (9.7)1,2 10 (12.8)1,2 583 (23.8)
Lives with spouse or partner 1221 (58.4) 60 (44.1) 105 (72.9) 62 (79.5) 1448 (59.2)
Other living arrangements 344 (16.5) 42 (30.9) 25 (17.4) 6 (7.7) 417 (17.0)
Independence
Able to live independently 732 (35.0) 42 (30.9)1 32 (22.2)1 27 (34.6) 833 (34.0)
Requires assistance 1304 (62.3) 79 (58.1) 105 (72.9) 48 (61.5) 1536 (62.7)
Completely dependent 45 (2.2) 15 (11.0) 7 (4.9) 1 (1.3) 68 (2.8)
Type of residence, N (%)
Single family residence 1709 (81.8) 90 (66.2)1 118 (81.9) 73 (93.6)2 1990 (81.3)
Retirement community 200 (9.6) 17 (12.5) 9 (6.3) 3 (3.9) 229 (9.4)
Assisted living 149 (7.1) 23 (16.9) 13 (9.0) 1 (1.3) 186 (7.6)
Other/unknown 32 (1.5) 6 (4.4) 4 (2.8) 1 (1.3) 43 (1.7)
Comorbidities, N (%)*
Psychiatric disorders 167 (8.0) 10 (7.4) 14 (9.7) 8 (10.3) 199 (8.1)
Cardiovascular diseasey 1479 (70.8) 119 (87.5)1 102 (70.8)2 49 (62.8)2 1749 (71.4)
Stroke 166 (7.9) 83 (61.0)1 9 (6.3)2 2 (2.6)2 260 (10.6)
Diabetes (type 1 or type 2) 297 (14.2) 29 (21.3) 11 (7.6)2 9 (11.5) 346 (14.1)
BMI (kg m22) 25.3 (4.5) 25.8 (4.8) 25.7 (4.1) 25.8 (5.0) 25.3 (4.5)
Years smoked cigarettes, mean (SD) 11.1 (16.1) 14.8 (19.7)1 11.5 (15.0) 9.1 (13.9) 11.2 (16.2)
Global Clinical Dementia Rating, N (%)
Questionable impairment 1167 (55.8) 63 (46.3)1 68 (47.2)1 44 (56.4) 1342 (54.8)
Mild impairment 832 (39.8) 54 (39.7) 63 (43.8) 29 (37.2) 978 (40.0)
Moderate impairment 74 (3.5) 12 (8.8) 8 (5.6) 4 (5.1) 98 (4.0)
Severe impairment 17 (0.8) 7 (5.2) 5 (3.5) 1 (1.3) 30 (1.2)
Total Geriatric Depression Scale
0–4 1569 (82.5) 84 (77.1) 82 (62.6)1 42 (71.2)1 1777 (72.6)
5–9 292 (15.3) 21 (19.3) 38 (29.0) 10 (17.0) 361 (14.7)
10–15 32 (1.7) 4 (3.7) 9 (7.1) 6 (9.8) 51 (2.1)
Medication exposures
Number of medications, mean (SD) 7.2 (4.1) 8.3 (4.3)1 8.0 (3.8) 5.9 (3.3) 1–3 7.3 (4.1)
Anticholinergic Drug Scale score, N (%)
0 1126 (53.9) 60 (44.1) 54 (37.5)1 45 (57.7)3 1285 (52.5)
1 488 (23.4) 38 (27.9) 40 (27.8) 19 (24.4) 585 (23.9)
2 140 (6.7) 12 (8.8) 17 (11.8) 3 (3.4) 172 (7.0)
3 336 (16.1) 26 (19.1) 33 (22.9) 11 (14.1) 406 (16.6)
Number of Beers’ Criteria medications, N (%)
0 763 (36.5) 48 (35.3) 51 (35.4) 34 (43.6) 896 (36.6)
1 824 (39.4) 51 (37.5) 48 (33.3) 31 (39.7) 954 (39.0)
2 357 (17.1) 23 (16.9) 27 (18.8) 10 (12.8) 417 (17.0)
3 146 (7.0) 14 (10.3) 18 (12.5) 3 (3.9) 181 (7.4)
Abbreviations: BMI, body mass index; SD, standard deviation.
NOTE. 1–3 indicates a pairwise difference (P , .05) with: 1Alzheimer’s disease, 2vascular dementia, and 3Lewy body dementia.
*Based on self-report of participant or informant.
yMyocardial infarction, atrial fibrillation, angioplasty, coronary artery bypass graft surgery, pace maker, congestive heart failure, or other cardiovascular disease.
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increased by 10% for AD (LSM: 1.10, 95% CI: 1.07–1.13)
and 15% for LBD (LSM: 1.15, 95% CI: 1.04–1.26)
(Fig. 3C); however, there was no change in the second year
after diagnosis for either type of dementia.
3.3. Attrition and sensitivity analysis
We examined differential attrition by type of dementia
(Table 2). At 1 year following dementia diagnosis, 38.2%
of participants with VD, 24.5% with AD, 27.1% with
LBD, and 20.5% with FTD were dead or lost to follow-up.
At 2 years, 44.1% of AD, 38.9% of LBD, 29.4% of VD,
and 30.8% of FTD participants were still active in the study.
A sensitivity analysis indicated that although point estimates
differed between the study sample (n 5 2448) and the sam-
ple with complete data (n 5 833), overall significance and
direction of the estimates between the two samples were
similar (results available upon request).
4. Discussion and conclusions
This is the first study to longitudinally investigate PIM
use according to dementia types following incident dementia
diagnosis. Our results suggest that PIM use in the first 2
years following diagnosis differs by type of dementia. Older
adults diagnosed with LBD reported higher PIM use
compared with adults diagnosed with AD. Moreover, adults
with FTD reported lower PIM use compared with adults with
AD, whereas adults with AD and VD did not differ in PIM
use.
Our findings are consistent with a previous cross-
sectional study, which found that individuals with LBD
were receiving more PIM medication including psychotro-
pics compared to individuals with other types of dementia
[49]. In our study, adults with LBD were less independent,
had more cognitive impairment, and more symptoms of
depression at baseline than participants with AD. This could
indicate a greater overall medical burden and a need for spe-
cific, and PIMs.
Similarly, our finding of less overall medication use in
FTD could be attributed to lower overall disease burden in
this younger subset of participants. However, baseline prev-
alence of health conditions other than depression did not
differ between participants and FTD and AD in our sample.
A previous study has suggested that language deficits in FTD
could interfere with the expression of some behavioural and
psychological symptoms that lead to pharmacological treat-
ment [49]. Although participants with FTD did not differ
from those with AD on overall levels of cognitive impair-
ment at baseline, we did not examine specific subsets of be-
havioural and psychological symptoms in this study.
Given the additional cardiovascular disease burden and
associated depression that characterize VD, we expected
more PIM use in this subgroup. Although we did observe
less independence; more cardiovascular, cerebrovascular,
and metabolic risk factors; and more cognitive impairment
at baseline, there were no differences between VD and AD
in PIM use over the follow-up when we adjusted for these
risk factors. However, 27.9% of participants with VD died
in the first year following their dementia diagnosis while
only 8.4% of participants with AD were deceased by 1
year. Therefore, it is possible that VD represents an older
and sicker subtype of dementia, and future studies of PIM
use should examine death as a competing risk.
This study also examined changes in PIM use in the 2 years
following diagnosis of different types of dementia. Overall,
there was some evidence to suggest an increase in PIM use
following diagnosis of LBD and AD. On average, the total
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number of medications increased following diagnosis of
dementia for participants with AD and LBD. For both diagno-
ses, total number of medications increased in the first year af-
ter diagnosis and did not change in the second year.
Participants diagnosed with LBD also had a significant in-
crease in their ADS scores in the first year following diagnosis
followed by a return to baseline levels in the second year.
From a clinical perspective, the fact that we did not find an
increase in Beers’ Criteria medications or a sustained increase
ADS scores following any type of dementia diagnosis sug-
gests that prescribers are aware of the potential harms of these
medications. However, nearly two-thirds of participants were
taking 1 Beers’ Criteria medication at the time of their de-
mentia diagnosis, and 75.2% reported taking 1 Beers’
Criteria medications at some point over the follow-up. Simi-
larly, nearly half of participants had an ADS score1 at base-
line, and 59% had an ADS score 1 for at least one
assessment point. Given the additional risk of PIM use among
persons with dementia [1,11] that we did not find a reduction
in use of Beers’ Criteria medications or ADS scores following
dementia diagnosis is concerning.
This study had several limitations to consider when eval-
uating the implications of our findings. First, participants in
the NACC cohort tend to be more educated, have higher
income; therefore, results may not generalize to other
populations. Second, given the advanced age and comorbid-
ities of participants, the rate of attrition over the 2-year
follow-up was high, and we cannot rule out a potential
healthy survivor effect. Although we conducted a sensitivity
analysis to examine the potential impact of attrition on our
outcomes, examining the relationships between type of de-
mentia, PIM use, and mortality is an important area of future
study. Third, assessments occur at 1-year intervals and do
not capture changes between visits. Hence, dementia diag-
nosis does not indicate the actual date of dementia onset,
and medications may be started and stopped between annual
visits. Given that medication use asked about current medi-
cations, participants may have been misclassified as not
exposed to any PIMs in the situation in which they started
and stopped treatment between two consecutive study visits.
Fourth, we were not able to assess specific indication for the
PIMS examined in this study (i.e., the used of antipsychotic
medications to treat hallucinations in participants with
LBD). Finally, although this study is strengthened by the in-
clusion of participants with LBD and other non-Alzheimer’s
dementias, the number of participants with non-AD demen-
tias was low (a limitation of most large-scale dementia
cohort studies), particularly by the 2-year follow-up. Despite
these limitations, this is the first study to examine PIM use
longitudinally following a dementia diagnosis and to
compare four different types of dementia. Our study is
further strengthened by standardized data collection
methods, extensive neurocognitive assessments and clinical
evaluations that support dementia diagnoses for study partic-
ipants, and the ability to assess both prescription and over-
the-counter medications.
Studying the use of PIMs over timewill improve our abil-
ity to treat and care for individuals with different types of de-
mentia. The results of our study further confirm evidence
from cross-sectional studies of the high prevalence of PIM
use among individuals with dementia [11]. Our study does
not provide evidence of deprescribing, even in a high-risk
sample of participants following a dementia diagnosis. Our
findings of differences in PIM use by type of dementia and
a lack of deprescribing following dementia diagnosis sug-
gests a need for a closer look at PIM use and interventions
aimed at optimal drug therapy to balance the risks and ben-
efits in older patients diagnosed with different types of
dementia.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional sources such as PubMed.While
longitudinal trends in use of potentially inappropriate
medication (PIM) following diagnosis of different
types of dementia has not been investigated, PIM
use in older adults with dementia has been studied
cross-sectionally. These recent studies are
appropriately cited.
2. Interpretation: Our findings suggest that PIM use
differs by type of dementia and that there is little
evidence of deprescribing of PIMs following a demen-
tia diagnosis.
3. Future directions: Further research is needed to better
understand long-term prescribing practices, risk
factors, and clinical outcomes according to types of
dementia.
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